Showing 1521-1530 of 1697 results for "".
- Paramagnetic Rim Lesions May Support Diagnosis in People with Suspected MShttps://practicalneurology.com/news/paramagnetic-rim-lesions-show-diagnostic-value-in-multiple-sclerosis-clinics/2483418/Paramagnetic rim lesions (PRLs), which are visible on susceptibility-based MRI, may serve as a useful diagnostic marker in people undergoing evaluation for multiple sclerosis (MS), according to a new study published in Neurology. The presence of PRLs was associated with increased diagnos
- GLP-1 Receptor Agonists Linked to Better Outcomes in Idiopathic Intracranial Hypertension Than Standard Therapyhttps://practicalneurology.com/news/glp-1-receptor-agonists-linked-to-better-outcomes-in-idiopathic-intracranial-hypertension-than-standard-therapy/2483417/Results from a large retrospective study published in JAMA Neurology suggest that glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy may offer benefits for patients with idiopathic intracranial hypertension (IIH). Compared with conventional therapies, GLP-1 RA use was associated
- Education May Not Prevent or Slow Cognitive Decline According to Results of a Large-Scale Longitudinal Cohort Studyhttps://practicalneurology.com/news/education-may-not-prevent-or-slow-cognitive-decline-according-to-results-of-a-large-scale-longitudinal-cohort-study/2483014/Education may have a smaller role in slowing cognitive decline and improving brain health than previously thought, according to new study results published in Nature Medicine. Educational attainment was associated with better cognitive performance in later life, higher memory test scores
- Four-Year Clarity-AD Data Show Slower Clinical Decline with Leqembi Treatmenthttps://practicalneurology.com/news/four-year-clarity-ad-data-show-slower-clinical-decline-with-leqembi-treatment/2475914/According to new 48-month data from the Clarity-AD (NCT03887455) open-label extension (OLE) study presented at the 2025 meeting of the Alzheimer’s Association International Conference (AAIC), individuals with early Alzheimer disease (AD) who received continuous treatment with Leqembi (lecanemab-i
- US POINTER Study Results: A Structured Lifestyle Intervention Improved Cognition in Older Adultshttps://practicalneurology.com/news/us-pointer-study-results-a-structured-lifestyle-intervention-improved-cognition-in-older-adults/2475903/Findings from the US POINTER clinical trial (NCT03688126) were presented at the 2025 meeting of the Alzheimer’s Association International Conference (AAIC), demonstrating significant benefits linked to lifestyle interventions for older adults at risk of cognitive decline and dementia. According t
- Intra-Arterial Tenecteplase After Successful Thrombectomy Improves Functional Outcomes in People with Large Vessel Occlusionhttps://practicalneurology.com/news/intra-arterial-tenecteplase-after-successful-thrombectomy-improves-functional-outcomes-in-people-with-large-vessel-occlusion/2475573/Adjunct intra-arterial TNKase (tenecteplase; Genentech, South San Francisco, CA) was associated with significant improvements in 90-day functional outcomes in individuals with acute ischemic stroke due to large vessel occlusion (LVO) presenting 4.5 to 24 hours prior to randomization who had alrea
- Imaavy Outperforms Other FcRn Blockers in Sustained gMG Symptom Controlhttps://practicalneurology.com/news/imaavy-outperforms-other-fcrn-blockers-in-sustained-gmg-symptom-control/2475453/Results of an indirect treatment comparison (ITC) demonstrated that Imaavy (nipocalimab-aahu; Johnson & Johnson, New Brunswick, NJ) treatment was associated with consistent and sustained improvement in generalized myasthenia gravis (gMG) symptoms in individuals aged ≥12 years with anti-acetyl
- Skin Biopsy Detects Synuclein Pathology in 75% of Those with Idiopathic REM Sleep Behavior Disorderhttps://practicalneurology.com/news/skin-biopsy-detects-synuclein-pathology-in-75-of-those-with-idiopathic-rem-sleep-behavior-disorder/2475314/According to study results presented at the 2025 Annual Meeting of the Associated Professional Sleep Societies (APSS), 75% of people with idiopathic rapid eye movement (REM) sleep behavior disorder (iRBD) and no evidence of other neurodegenerative disease tested positive for cutaneous phosphoryla
- Novel Multi-Modal Screening Method for Classification of Narcolepsy Type 1 is Highly Specific and Sensitivehttps://practicalneurology.com/news/novel-multi-modal-screening-method-for-classification-of-narcolepsy-type-1-is-highly-specific-and-sensitive/2475086/Study results presented at the 2025 Annual Meeting of the Associated Professional Sleep Societies (APSS) demonstrated the specificity and sensitivity of a large-scale screening model for the classification of narcolepsy type 1 (NT1) which integrates polygenic risk scores (PRS), human leukocyte an
- Sunosi Significantly Reduced Excessive Daytime Sleepiness and Obstructive Sleep Apnea Symptoms in Real-World Studyhttps://practicalneurology.com/news/sunosi-significantly-reduced-excessive-daytime-sleepiness-and-obstructive-sleep-apnea-symptoms-in-real-world-study/2475070/The results of a real-world analysis presented at the 2025 Annual Meeting of the Associated Professional Sleep Societies (APSS) show that Sunosi (solriamfetol; Axsome Therapeutics, New York, NY) significantly reduced symptoms of excessive daytime sleepiness (EDS) in individuals with obstructive s